Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Findings of women's health initiative trial need not alarm users
| The first 150 words of the full text of this article appear below. |
Observational studies have suggested a major health
benefit of postmenopausal hormone replacement therapy, including
reductions in coronary heart disease, osteoporotic fractures, and
colorectal cancer. Such studies have also suggested an increased risk
for breast cancer and possibly stroke. Critics have said that the benefits, but not the risks, may simply reflect a healthy user bias and
have demanded randomised trials. The women's health initiative is a
randomised trial of these health outcomes to assess risks and benefits
of intervention strategies in a postmenopausal population. The trial
has shown harm for cardiovascular diseases, including coronary heart
disease (the primary outcome) and stroke, although it showed benefits
for hip fractures and bowel cancer. The relative risks for invasive
breast cancer, coronary heart disease, and stroke were increased,
although the absolute risks were very small. The findings may not be
the same for types of hormone replacement therapy other than those used
in
Read all Rapid Responses